Literature DB >> 25205719

Cathepsin B-deficient mice as source of monoclonal anti-cathepsin B antibodies.

Ekkehard Weber, Elena Barbulescu, Rita Medek, Thomas Reinheckel, Mansoureh Sameni, Arulselvi Anbalagan, Kamiar Moin, Bonnie F Sloane.   

Abstract

Cathepsin B has been demonstrated to be involved in several proteolytic processes that support tumor progression and metastasis and neurodegeneration. To further clarify its role, defined monoclonal antibodies are needed. As the primary structure of human cathepsin B is almost identical to that of the mouse, cathepsin B-deficient mice were used in a novel approach for generating such antibodies, providing the chance of an increased immune response to the antigen, human cathepsin B. Thirty clones were found to produce cathepsin B-specific antibodies. Seven of these antibodies were used to detect cathepsin B in MCF10-DCIS human breast cancer cells by immunocytochemistry and immunoblotting. Five different binding sites were identified by epitope mapping giving the opportunity to combine these antibodies in oligoclonal antibody mixtures for an improved detection of cathepsin B.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25205719      PMCID: PMC4496956          DOI: 10.1515/hsz-2014-0191

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  31 in total

Review 1.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

2.  Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice.

Authors:  L Sevenich; F Werner; M Gajda; U Schurigt; C Sieber; S Müller; M Follo; C Peters; T Reinheckel
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

Review 3.  Lysosomes as targets for cancer therapy.

Authors:  Nicole Fehrenbacher; Marja Jäättelä
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

Review 4.  Cysteine cathepsins: multifunctional enzymes in cancer.

Authors:  Mona Mostafa Mohamed; Bonnie F Sloane
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

5.  Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro.

Authors:  M Murata; S Miyashita; C Yokoo; M Tamai; K Hanada; K Hatayama; T Towatari; T Nikawa; N Katunuma
Journal:  FEBS Lett       Date:  1991-03-25       Impact factor: 4.124

6.  Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors.

Authors:  Ales Bervar; Irena Zajc; Natasa Sever; Nobuhiko Katunuma; Bonnie F Sloane; Tamara T Lah
Journal:  Biol Chem       Date:  2003-03       Impact factor: 3.915

7.  Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins.

Authors:  Stefanie R Mullins; Mansoureth Sameni; Galia Blum; Matthew Bogyo; Bonnie F Sloane; Kamiar Moin
Journal:  Biol Chem       Date:  2012-12       Impact factor: 3.915

Review 8.  Cathepsin B and its role(s) in cancer progression.

Authors:  Izabela Podgorski; Bonnie F Sloane
Journal:  Biochem Soc Symp       Date:  2003

9.  Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice.

Authors:  Aarthi Gopinathan; Gina M Denicola; Kristopher K Frese; Natalie Cook; Florian A Karreth; Julia Mayerle; Markus M Lerch; Thomas Reinheckel; David A Tuveson
Journal:  Gut       Date:  2011-12-09       Impact factor: 31.793

10.  Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.

Authors:  Thomas Reinheckel; Christoph Peters; Achim Krüger; Boris Turk; Olga Vasiljeva
Journal:  Front Pharmacol       Date:  2012-07-11       Impact factor: 5.810

View more
  1 in total

1.  Elevated mRNA expression and defective processing of cathepsin D in HeLa cells lacking the mannose 6-phosphate pathway.

Authors:  Lin Liu; Balraj Doray
Journal:  FEBS Open Bio       Date:  2021-05-05       Impact factor: 2.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.